Literature DB >> 1332442

Structural analysis of periodate-oxidized heparin.

H E Conrad1, Y Guo.   

Abstract

Treatment of heparin with HONO at pH 1.5 cleaves the polymer at N-sulfated, but not at N-acetylated GlcN residues, and yields di- and tetrasaccharides. The GlcNSO3 residues at the sites of cleavage are converted into anhydromannose (AMan) residues. Reduction of heparin cleavage products with NaB3H4 yields mixtures of di- and tetrasaccharides with reducing terminal [3H]anhydromannitol residues. The identification and quantification of these oligosaccharides by HPLC procedures have been described. These procedures have been used to determine the rates of periodate oxidation of the susceptible unsulfated GlcA and IdoA residues in heparin by measuring the disappearance of the di- and tetrasaccharides that contain GlcA and IdoA. Complete oxidation with IO4- results in the total loss of the unsulfated uronic acid-containing oligosaccharides, but kinetic studies reported here show that IdoA is oxidized much more rapidly than the major fraction of the GlcA under all reaction conditions. As the pH is lowered from 7 down to 3, the overall rate of the oxidation slows markedly, but the relative rates of GlcA and IdoA oxidation do not change. The slow rate of oxidation of GlcA residues at all pH's yields oxidation products early in the reaction progress in which all of the unsulfated IdoA residues are oxidized while 70-80% of the pH 1.5 nitrous acid-releasable GlcA----AMan(3,6-(SO4)2) are retained. The anticoagulant activity (APTT) of the partially oxidized product is reduced from 170 IU/mg to 38 IU/mg. Further studies show that the GlcA residue in the antithrombin III binding pentasaccharide is oxidized much more rapidly than the bulk of the GlcA residues in heparin. The results suggest that heparin contains GlcA----AMan(3,6-(SO4)2) sequences that lie outside of the antithrombin-binding pentasaccharide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332442     DOI: 10.1007/978-1-4899-2444-5_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Michela Asperti; Annamaria Naggi; Natascia Campostrini; Domenico Girelli; Michela Corbella; Marina Benzi; Celine Besson-Fournier; Helene Coppin; Federica Maccarinelli; Dario Finazzi; Paolo Arosio
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

2.  Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

Authors:  Anna Alekseeva; Benito Casu; Giangiacomo Torri; Sabrina Pierro; Annamaria Naggi
Journal:  Anal Biochem       Date:  2012-11-29       Impact factor: 3.365

Review 3.  Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.

Authors:  Cinzia Lanzi; Giuliana Cassinelli
Journal:  Molecules       Date:  2018-11-08       Impact factor: 4.411

4.  Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung.

Authors:  K Ono; M Ishihara; K Ishikawa; Y Ozeki; H Deguchi; M Sato; H Hashimoto; Y Saito; H Yura; A Kurita; T Maehara
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.